Vision & Mission
Combining cancer vaccines
and T-cell therapies
ErVimmune develops breakthrough immunotherapies combining cancer vaccines and T-cell therapies based on the identification of new families of tumor antigens.
We are dedicated to discover more accurate tumor epitopes that are shared between patients. We focus on non-conventional epitopes derived from endogenous retroviruses (HERVs).
Our approach is based on new bioinformatics algorithms to identify potential epitopes that are validated by proteomics and immunology assays: from bioinformatics to proteomics.
Paola Bonaventura, project leader at ErVaccine Technologies, has been giving a talk entitled “Human Endogenous Retrovirus (HERVs) Represent a...
Stéphane Depil, founder and CEO of ErVaccine Technologies, will give a talk entitled “Human Endogenous Retrovirus Represent a Source of Shared...
ErVaccine Technologies, in collaboration with Centre Leon Berard hospital / Cancer Research Center of Lyon, is thrilled to announce the selection of...
Publications & abstracts
Les rétrovirus endogènes humains (HERVs) caractérisent les différentes sous-populations cellulaires normales et leucémiques et constituent un réservoir d’épitopes pour le développement d’immunothérapies dans la LAM
CIMT 2021 – Identification of shared tumor epitopes from endogenous retroviruses inducing high avidity cytotoxic T cells for cancer immunotherapy
Medical research and development, in particular the development of new families of tumour antigens.
Research, development and production of monoclonal antibodies and derivatives targeting new membrane antigens and any other activity of any nature whatsoever related to the biotechnology and/or pharmaceutical industry.
> Publications & abstracts
> Recent news
> Legal notice
> About us
> Join us
28 RUE LAENNEC
69008 LYON FRANCE
+33 6 67 67 44 97